glp-1 drugs adverse effects medication side for diabetes and weight loss GLP-1: Genetic Variants Related to

(PubMed) Side Effect Profile GI effects (nausea, vomiting, diarrhea/constipation) Similar GI-class effects are commonly reported (especially during dose escalation phases in medical use contexts)

According to Lilly, retatrutide is not yet available to the public, is not FDA-approved, and is still being studied in Phase 3 trials

Overall, tirzepatides dual agonism of GLP1 and GIP receptors appears to provide encouraging cardiovascular benefits beyond glycemic control, offering a potential new therapeutic option for treating cardiovascular diseases and heart failure

Published July 13, 2022

Giugliano, D

All DPP4 inhibitors have in common that they build salt bridges with Glu-residues in the S2 subsite (10)